Preterm birth recurrence after spontaneous preterm birth between 16-28 weeks: A national cohort study by Annabelle L. Van Gils, Anita C. Ravelli, Esmé I. Kamphuis, Brenda M. Kazemier, Eva Pajkrt, Martijn A. Oudijk, Marjon A. De Boer

Get full text

Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up by Martijn A Oudijk, Madelon van Wely, Eva Pajkrt, Job Klumper, Aleid G van Wassenaer-Leemhuis, Emilie V J van Limburg Stirum, Janneke Van 't Hooft, Larissa van der Windt

Get full text

Study protocol for a randomised trial for atosiban versus placebo in threatened preterm birth: the APOSTEL 8 study by Ben W Mol, Fionnuala McAuliffe, Martijn A Oudijk, Christiana A Naaktgeboren, Jim Thornton, Ewoud Schuit, Job Klumper, Wouter Breebaart, Carolien Roos, Joris van der Post, Judith Bosmans, Anton van Kaam, Jelle Baalman, Marjolein Kok

Get full text

Correction: Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study by Melanie A van Os, Jeanine A van der Ven, C Emily Kleinrouweler, Eva Pajkrt, Esteriek de Miranda, Aleid van Wassenaer, Martina Porath, Patrick M Bossuyt, Kitty WM Bloemenkamp, Christine Willekes, Mallory Woiski, Martijn A Oudijk, Katia M Bilardo, Marko J Sikkema, Johannes J Duvekot, Diederik Veersema, Jacqueline Laudy, Petra Kuiper, Christianne JM de Groot, Ben Willem J Mol, Monique C Haak

Get full text